Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD) : A randomised clinical trial
Objective: Intravenous iron - a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD) - can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or ferric derisomaltose (FDI). Design: This randomised, double-blind, clinical trial was conducted at 20 outpatient hospital clinics in Europe (